COMP <GO>
PBH vs NAMS // FORWARD P/E MULTIPLE
Prestige Consumer Healthcare Inc. (NYSE) VS. NewAmsterdam Pharma Company N.V. (NASDAQ) • 15-METRIC TALLY: PBH 7
— NAMS 2
■ METRIC PARITY
LAST: $49.73 (+1.37%) • MKT CAP: $2.32B
forward-pe
11.3x
LAST: $19.56 (-2.49%) • MKT CAP: $2.40B
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. NAMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBH | NAMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | -35.00% | +48.80 | PBH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 10.67% | -5.96% | +16.63 | PBH | /fcf-yield <GO> |
| Operating Margin | 28.40% | -60.00% | +88.40 | PBH | /operating-margins <GO> |
| Net Profit Margin | 17.50% | -60.00% | +77.50 | PBH | /net-margins <GO> |
| Revenue Growth (YoY) | -4.30% | -50.60% | +46.30 | PBH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 15.94 | -13.73 | NAMS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 3/9 | +3.00 | PBH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.0 | 41.9 | +12.10 | PBH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 11.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.32B | $2.40B | -$73.7M | NAMS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBH REV | NAMS REV | PBH GROSS % | NAMS GROSS % | PBH FCF | NAMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.09B | $22.5M | 54.7% | — | $246.4M | -$147.8M |
| FY 2024 | $1.14B | $45.6M | 55.8% | — | $243.3M | -$158.6M |
| FY 2023 | $1.13B | $14.1M | — | — | $248.9M | -$141.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
NAMS // BETA —